2-Aryl-3,6-dialkyl-5-dialkylaminopyrimidin-4-ones as novel crf-1 receptor antagonists.
The discovery, synthesis and structure-activity studies of a novel series of 2-arylpyrimidin-4-ones as CRF-1 receptor antagonists is described. These compounds are structurally simple and display appropriate physical properties for CNS agents
Hodgetts
Kevin J
KJ
Neurogen Corporation, 35NE Industrial Road, Branford, CT 06405, USA.
Yoon
Taeyoung
T
Huang
Jianhua
J
Gulianello
Michael
M
Kieltyka
Andrzej
A
Primus
Renee
R
Brodbeck
Robbin
R
De Lombaert
Stéphane
S
Doller
Darío
D
D055598:Chemical Phenomena; D002627:Chemistry, Physical; D015195:Drug Design; D006801:Humans; D066298:In Vitro Techniques; D007202:Indicators and Reagents; D008861:Microsomes / Q000187:drug effects; D011743:Pyrimidines / Q000138:chemical synthesis* / Q000494:pharmacology*; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship; D000099052:CRF Receptor, Type 1
D007202:Indicators and Reagents; D011743:Pyrimidines; D018019:Receptors, Corticotropin-Releasing Hormone; D000099052:CRF Receptor, Type 1